Browse > Article

Bisphophonate-Related Osteonecrosis of the Jaw (BRONJ)  

Kim, Hyeon-Mook (Sunplus Dental Clinic)
Park, Chan-Jin (Department of Prosthodontics and Institute of Oral Science, College of Dentistry, Gangneung-Wonju National University)
Publication Information
Journal of Dental Rehabilitation and Applied Science / v.27, no.4, 2011 , pp. 449-454 More about this Journal
Abstract
Recently, jawbone osteonecrosis has been largely reported as a potential adverse effect of bisphosphonate (BP)administration. Currently available published incidence data for BRONJ are based on retrospective studies and estimates of cumulative incidence range from 0.8 to 12%. The mandible is more commonly affected than the maxilla (2:1 ratio), and 60-70% of cases are preceded by a dental surgical procedure. The signs and symptoms that may occur before the appearance of clinical evident osteonecrosis include changes in the health of periodontal tissues, non-healing mucosal ulcers, loose teeth and unexplained soft-tissue infection. Tooth extraction as a precipitating event is a common observation. The significant benefits that bisphosphonates offer to patients clearly surpass the risk of potential side effects; however, any patient for whom prolonged bisphosphonate therapy is indicated, should be provided with preventive dental care in order to minimize the risk of developing this severe condition.
Keywords
bisphosphonate; dental treatment; osteonecrosis; BRONJ;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Wu S, Dahut WL, Gulley JL. The use of bisphosphonates in cancer patients. Acta Oncol 2007;46:581- 91   DOI   ScienceOn
2 Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003;61:1104-7   DOI   ScienceOn
3 Rosenberg TJ, Ruggiero S. Osteonecrosis of the jaws associated with the use of bisphosphonates. J Oral Maxillofac Surg 2003;61:60 (letter)   DOI   ScienceOn
4 Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-7   DOI   ScienceOn
5 Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. New Engl J Med 2003;21: 4253-4 (letter)
6 Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34   DOI   ScienceOn
7 Lugassy G, Shaham R, Nemets A, et al. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med 2004;117:440-1   DOI   ScienceOn
8 Bagan JV, Murillo J, Poveda R, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005;34:120-3   DOI   ScienceOn
9 Vannucchi AM, Ficarra G, Antonioli E, et al. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol 2005;128:738   DOI   ScienceOn
10 Yarom N, Yahalom Y, Shoshani, et al. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007;18(10):1363-70   DOI   ScienceOn
11 Lehrer S, Montazem A, Ramanathan L, Pessin- Minsley M, Pfail J, Stock RG, et al. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 106 : 389-91.   DOI   ScienceOn
12 Kos M, Kuebler JF, Luczak K, Engelke W. Bisphosphonate related osteonecrosis of the jaws: a review of 34 cases and evaluation of risk. J Craniomaxillofac Surg 2010; 38 : 255-9.   DOI   ScienceOn
13 Migliorati CA, Schubert MM, Peterson DE, et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93   DOI   ScienceOn
14 Merigo E, Manfredi M, Meleti M, et al. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four- case report. J Oral Pathol Med 2005;34:613-7   DOI   ScienceOn
15 Olson KB, Hellie CM, Pienta KJ. Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid. Urology 2005;66:658
16 Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single- centre experience in 303 patients. Br J Haematol 2006;134:620-3   DOI   ScienceOn
17 Sanna G, Preda L, Bruschini R, et al. Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann Oncol 2006;17:1512-6   DOI   ScienceOn
18 Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945- 52   DOI   ScienceOn
19 American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonates-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-76   DOI   ScienceOn
20 Ficarra G, Beninati F. Bisphosphonate-related osteonecrosis of the jaws: an update on clinical, pathological and management aspects. Head Neck Pathol 2007; 1 : 132-40.   DOI   ScienceOn
21 Reid IR, Bolland MJ. Is bisphosphonates-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007;41:318-20   DOI   ScienceOn